Why Janux Therapeutics, Inc.’s (JANX) Stock Is Down 6.54%
As of Thursday, November 12, Janux Therapeutics, Inc.’s JANX share price has dipped by 6.54%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Jenna Brashear
Rosalio Madrigal
Rosalio Madrigal
| Share Statistics | JANX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $617.0 | $203.5 | 41% |
|
| Shares Out (Mil) | 63.1 | 55.2 | 52% |
|
| Institutional Ownership | 98.7% | 93.3% | 81% |
|
| Float (Mil) | 45.6 | 40.4 | 44% |
|
| Beta | 2.39 | 1.05 | 95% |
|
| Avg Daily Volume (000s) | 1,455 | 569 | 75% |
|
| Price Change (52-week) |
(65.0%) | 38.8% | 15% |
|
| Growth | JANX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (75.6%) | (10.7%) | 3% |
|
| EPS (5yr) | 24.4% | 15.4% | 75 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (22.7%) | (15.7%) | 29% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 15 | 15 | 14 | |
| Current EPS | ($0.511) | ($1.574) | ($2.552) | |
| Month Ago EPS | ($0.566) | ($1.732) | ($2.624) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 4 | 1 | 1 | |
| Three Months Ago EPS | ($0.585) | ($1.758) | ($2.639) | |
| Year/Year Chg | 49.4% | (14.2%) | 76.4% | |
| Financials | JANX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $23 | $40 | 14% |
|
| Net Income (TTM) (Mil) | ($100) | ($44) | 11% |
|
| EPS (TTM) | ($1.592) | ($1.400) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($54) | ($35) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($7) | $-0 | 35% |
|
| Long-Term Debt (Q1) (Mil) | $18 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $153 | $142 | 25% |
|
| Valuation | JANX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.68 | 1.96 | 18% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | JANX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (414.9%) | 67.6% | 0% |
|
| Net Margin | (428.7%) | (50.8%) | 2% |
|
| ROA | (9.9%) | (47.0%) | 25% |
|
| ROE | (10.6%) | (51.8%) | 27% |
|
| Liabilities to Assets | 7.3% | 29.6% | 4% |
|
| F-Score | 3 | 3 | 18% |
|
Janux Therapeutics, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors